Leprosy

Introduction, Causative Agent, and Transmission

Leprosy, also known as Hansen's disease, is a chronic infectious disease caused by the bacterium Mycobacterium leprae. This acid-fast bacillus primarily targets the peripheral nerves, skin, upper respiratory tract mucosa, and eyes. Despite common fears, leprosy has a low level of infectiousness and transmission requires prolonged, close contact with untreated cases.

• Droplet infection: The primary route of transmission is through droplets from the nose and mouth during close and frequent contacts with untreated cases.
• Skin contact: Broken skin contact with secretions from lepromatous lesions may also play a role, though it is less common.
• Incubation period: This is notoriously long, averaging between three to five years, but can range from one year to twenty years.

Classification and Clinical Types

The clinical manifestation of leprosy depends entirely on the patient's cell-mediated immune response. The World Health Organization (WHO) classifies leprosy operationally into two main groups for treatment purposes, based on skin smear results.

Signs, Symptoms, and Clinical Assessment

Clinical assessment centers on identifying dermatological and neurological deficits. The hallmark sign of leprosy is a skin lesion that shows a definite loss of sensation. Patients may present with patches that are paler or darker than their surrounding skin, which feel numb to touch, pain, and temperature.

Peripheral nerve enlargement is another cardinal sign. Nurses must palpate common superficial nerves such as the ulnar, median, radial, lateral popliteal, and posterior tibial nerves for thickening and tenderness. Muscle weakness, such as claw hand or foot drop, often develops as nerve damage progresses.

Complications, Reactions, and Disabilities

Without timely treatment, leprosy leads to severe nerve damage and permanent physical disabilities. A major clinical challenge is the occurrence of lepra reactions, which are acute inflammatory episodes that can cause rapid nerve function loss.

• Type 1 (Reversal Reaction): Cell-mediated immune response flare-up, causing existing skin lesions to become swollen, red, and inflamed, along with sudden nerve pain.
• Type 2 (Erythema Nodosum Leprosum): Immune-complex mediated reaction resulting in painful subcutaneous nodules, fever, and malaise.
• Secondary Impairments: Anesthesia in the hands and feet leads to painless burns, injuries, ulcers, and eventual resorption of digits.

Medical Management and Multi-Drug Therapy

Monotherapy for leprosy leads to rapid drug resistance, making Multi-Drug Therapy (MDT) the global standard of care introduced by the WHO. MDT combines bactericidal and bacteriostatic medications to kill the bacilli and prevent resistance.

• Rifampicin: A potent bactericidal drug given monthly (supervised) and daily in some regimens.
• Clofazimine: Has both antimycobacterial and anti-inflammatory properties, given daily and monthly.
• Dapsone: A bacteriostatic drug taken daily by the patient at home.

Treatment duration varies based on classification: Paucibacillary cases typically receive MDT for 6 months, while Multibacillary cases require treatment for 12 months or longer.

Nursing Care and Self-Care Practices

Nursing management focuses on administering medications, monitoring for adverse drug reactions, and teaching self-care to prevent secondary injuries in insensate limbs. Because patients cannot feel pain, they are vulnerable to trauma.

• Eye care: Patients with facial nerve involvement may experience lagophthalmos (inability to close eyes fully), requiring lubricating drops and protective glasses to prevent corneal ulceration.
• Foot care: Daily inspection of feet for cuts, soaking in warm water, applying cream to prevent cracking, and wearing protective footwear.
• Adherence counseling: Explaining the importance of completing the full course of MDT despite disappearing symptoms.

Community Prevention and Rehabilitation

Community-based interventions are vital for eliminating leprosy as a public health problem and reducing the stigma attached to the disease. Historically, leprosy caused severe social isolation.

• Contact tracing: Screening household members and close contacts of newly diagnosed patients for early signs of infection.
• Stigma reduction: Conducting health education campaigns to dispel myths that leprosy is a curse or highly contagious through casual touch.
• Physical and social rehabilitation: Providing reconstructive surgery for deformities, vocational training, and psychological support to reintegrate affected individuals into society.